Dr. William L. Clark, MD
Ophthalmology (Ophthalmology Physician)
124 Sunset Court
West Columbia, SC 29169
Who else practices at this address →
Lexington County includes mental health (100% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 743
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
SC license 21749 · NC license 9601270 -
Retina Specialist (Ophthalmology) Physician
SC license 21749
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Carolina East Medical Center New Bern, NC
Medical groups
- Retina Associates, PLLC (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 743
- Services billed
- 26,302
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 4,860 | 12 |
| Injection, aflibercept, 1 mg | 2,356 | 190 |
| Imaging of retina | 2,285 | 722 |
| Injection, ranibizumab, 0.1 mg | 1,892 | 106 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,774 | 87 |
| Injection of drug into eye | 1,737 | 353 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 390 | 17 |
| Established patient problem focused exam of visual system | 309 | 209 |
| Established patient office or other outpatient visit, 30-39 minutes | 230 | 214 |
| Unclassified drugs | 230 | 108 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in West Columbia, SC | 134 |
| Atropine Sulfate | 60 |
| Latanoprost Other prescribers in West Columbia, SC | 58 |
| Ofloxacin Other prescribers in West Columbia, SC | 55 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in West Columbia, SC | 50 |
| Brimonidine Tartrate Other prescribers in West Columbia, SC | 42 |
| Combigan (brimonidine tartrate/timolol) Other prescribers in West Columbia, SC | 32 |
| Ketorolac Tromethamine Other prescribers in West Columbia, SC | 29 |
| Dorzolamide Hcl Other prescribers in West Columbia, SC | 18 |
| Brimonidine Tartrate-Timolol (brimonidine tartrate/timolol) Other prescribers in West Columbia, SC | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 49 payments worth $46,824 in total to this clinician.
| Ocular Therapeutix, Inc. | $40,071 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $3,743 |
| Neurotech Pharmaceuticals, Inc. | $2,194 |
| Sandoz Inc. | $538 |
| Genentech USA, Inc. | $93.21 |
| Astellas Pharma US Inc | $56.18 |
| AbbVie Inc. | $41.91 |
| Apellis Pharmaceuticals, Inc. | $39.15 |
| Travel and Lodging | $28,047 |
|---|---|
| Consulting Fee | $14,717 |
| Compensation for services other than consulting (speaking, faculty) | $2,210 |
| Food and Beverage | $1,850 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ocular Therapeutix, Inc. Apr 6, 2025 | Travel and Lodging travel to Seville, SEVILLE, Spain · in-kind | $8,414 |
| Ocular Therapeutix, Inc. Apr 6, 2025 | Travel and Lodging travel to Seville, SEVILLE, Spain · in-kind | $6,250 |
| Ocular Therapeutix, Inc. Apr 1, 2025 | Travel and Lodging travel to Seville, SEVILLE, Spain · in-kind | $6,000 |
| Ocular Therapeutix, Inc. Apr 6, 2025 | Travel and Lodging travel to Seville, SEVILLE, Spain · in-kind | $4,781 |
| Regeneron Healthcare Solutions, Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $2,210 |
| Neurotech Pharmaceuticals, Inc. Oct 18, 2025 | Consulting Fee | $2,074 |
| Ocular Therapeutix, Inc. Mar 31, 2025 | Consulting Fee | $2,000 |
| Ocular Therapeutix, Inc. Mar 28, 2025 | Consulting Fee | $2,000 |
| Ocular Therapeutix, Inc. Apr 6, 2025 | Consulting Fee | $2,000 |
| Ocular Therapeutix, Inc. Oct 18, 2025 | Consulting Fee | $2,000 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Neurotech Pharmaceuticals, Inc. Oct 18, 2025 | Consulting Fee | $2,074 |
| Ocular Therapeutix, Inc. Oct 18, 2025 | Consulting Fee | $2,000 |
| Regeneron Healthcare Solutions, Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $2,210 |
| Ocular Therapeutix, Inc. May 12, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Apr 6, 2025 | Travel and Lodging travel to Seville, SEVILLE, Spain · in-kind | $8,414 |
| Ocular Therapeutix, Inc. Apr 6, 2025 | Travel and Lodging travel to Seville, SEVILLE, Spain · in-kind | $6,250 |
| Ocular Therapeutix, Inc. Apr 6, 2025 | Travel and Lodging travel to Seville, SEVILLE, Spain · in-kind | $4,781 |
| Ocular Therapeutix, Inc. Apr 6, 2025 | Consulting Fee | $2,000 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $1,105 |
| Ocular Therapeutix, Inc. Apr 1, 2025 | Travel and Lodging travel to Seville, SEVILLE, Spain · in-kind | $6,000 |
| Ocular Therapeutix, Inc. Mar 31, 2025 | Consulting Fee | $2,000 |
| Ocular Therapeutix, Inc. Mar 28, 2025 | Consulting Fee | $2,000 |
| Ocular Therapeutix, Inc. Mar 27, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Mar 13, 2025 | Consulting Fee | $1,000 |
| Ocular Therapeutix, Inc. Feb 18, 2025 | Travel and Lodging travel to Kauai, HI | $1,200 |
| Sandoz Inc. Feb 7, 2025 | Consulting Fee | $538 |
| Ocular Therapeutix, Inc. Jan 17, 2025 | Travel and Lodging travel to Kauai, HI · in-kind | $1,083 |
| Ocular Therapeutix, Inc. Jan 15, 2025 | Travel and Lodging travel to Kauai, HI · in-kind | $319 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $567,337 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Bayer HealthCare Pharmaceuticals Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - New Day Study
Ani Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.